MaaT-013 is under clinical development by MaaT Pharma and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MaaT-013’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MaaT-013 overview
MaaT-013 is under development for the treatment of metastatic melanoma and acute graft versus host disease. The therapeutic candidate comprises of allogenic fetal microbiota transplant, butycore. It is administered through rectal route in the form of enema. The drug candidate is developed based on Microbiome Restoration Biotherapeutic (MMRB) platform.
MaaT Pharma overview
MaaT Pharma (MaaT) is a biotechnology company that develops novel treatments for Gut Microbiota dysbiosis related diseases. The product portfolio in clinical development including one in Phase II are MaaT013 for the treatment of acute graft-versus-host disease and 1 in Phase Ib MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation and in preclinical development and MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors. It also develops treatment for infectious diseases related to onco-hematology in fragile patients. MaaT is headquartered in Lyon, France.
For a complete picture of MaaT-013’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
